Search Results
Your search for ,ShE matches 5598 pages
Showing 751 - 800A New Approach to Identifying Consumer Products That Contain Cancer-Causing Chemicals
Researchers may have uncovered a novel strategy to predict whether synthetic chemicals may cause breast cancer by examining their specific traits, according to a recent study published by Kay et al in Environmental Health Perspectives. Background The incidence of breast cancer—the most common...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
IO Strategies for Resectable NSCLC
This is Part 1 of New Directions in Nonmetastatic Non–Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Heather Wakelee, Tina Cascone, and Marina Garassino discuss immune checkpoint inhibitor strategies...
Patients With Advanced Breast Cancer May Gain Multiple Benefits From Exercise as Part of Palliative Care
Although current ASCO guidelines recommend exercise for patients with breast cancer during adjuvant therapy with curative intent, the guidelines state that more study is needed regarding the effects of exercise for patients with metastatic breast cancer. The results of the PREFERABLE-EFFECT trial...
Some Patients With Breast Cancer May Safely Avoid Locoregional Irradiation After Neoadjuvant Chemotherapy
It may be possible for some patients with breast cancer to avoid adjuvant regional nodal irradiation safely, according to the results of the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the 2023 San Antonio Breast Cancer Symposium.1 These findings particularly apply to patients...
Patient Choice of Location for Breast Cancer Surgery
Investigators have found that involving patients as partners in the treatment decision-making process may be a critical aspect of patient-centered care, according to a recent study published by Aggarwal et al in Cancer. Study Methods and Results In the study, the investigators used 2016 to 2018...
Treatment at Community Cancer Centers May Be Linked to Poorer Outcomes in Patients With HPV-Related Oropharyngeal Squamous Cell Carcinoma
Treatment in community cancer centers may be associated with a lower rate of survival among patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma of the oropharynx, according to a recent study published by Trakimas et al in the Journal of the National Cancer...
Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows Robust Activity in Refractory Small Cell Lung Cancer
The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...
Expert Point of View: Noemí Reguart, MD, PhD
Abstract discussant Noemí Reguart, MD, PhD, an oncologist at the Hospital Clinic Barcelona, underscored the “impressive” progression-free and overall survival results of the phase III ETER701 trial, which have “never been achieved before in extensive-stage small cell lung cancer.” According to...
Phase III Trial Shows Novel Four-Drug Regimen Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
The addition of anlotinib to immunochemotherapy has achieved the historically longest progression-free survival and overall survival in the first-line setting of extensive-stage small cell lung cancer, according to data presented at the International Association for the Study of Lung Cancer 2023...
Expert Point of View: Elizabeth Smyth, MD
Invited discussant of the phase I trial of the claudin 18.2-specific antibody-drug conjugate CMG901 in advanced gastric or gastroesophageal junction cancer was Elizabeth Smyth, MD, of Oxford University Hospitals NHS Foundation Trust. She said CMG901 demonstrated “encouraging results,” but more...
I Don’t Want Cancer to Define Me
Except for a series of unexplained multiple broken bones and inexplicable excruciating pain in my right hip and leg, I had no other hallmarks of multiple myeloma when I was diagnosed with the disease at age 48 in 2014. My blood test values were all normal, and I didn’t have anemia or kidney damage. ...
Implementation of Updated WHO Screening Guidelines Could Reduce Cervical Cancer Mortality by Over 50% in Lower-Income Countries
Investigators have found that implementing the updated World Health Organization (WHO) screening guidelines may effectively reduce the cervical cancer mortality rate in patients residing in low- and middle-income countries, according to two recent studies published by Simms et al and Hall et al in...
Melanoma in Younger Individuals
This is Part 4 of Evolving Skin Cancer Management, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Pauline Funchain, Alison Vidimos, and Lisa Zaba review the case of a 32-year-old patient who recently gave birth to her first...
Expert Point of View: Bonny Morris, PhD, RN, MSPH
Invited discussant Bonny Morris, PhD, RN, MSPH, of the American Cancer Society, underscored the significance of the study’s findings for the veteran community. “There are more than 50,000 veterans diagnosed with cancer each year, with the most common cancers being prostate, lung, and colorectal,”...
The Power of Patient Advocacy: 10-Year Study Reveals Increased Survival Rates With Enhanced Advance Care Planning
A decade-long journey toward improving end-of-life care for patients with advanced cancer has demonstrated positive effects on survival, health-care use, and cost of care, according to data presented at the 2023 ASCO Quality Care Symposium.1 Post hoc analysis of an advance care planning...
Expert Point of View: Susan Faye Dent, MD
In a joint ASCO/ICOS (International Cardio-Oncology Society) session presented at the 2023 Global Cardio-Oncology Summit, Dr. Anita Arnold and Dr. Krishnan Bhaskaran discussed the importance of understanding the impact of cancer therapy on the cardiovascular health of women. Medical oncologist...
Cardiovascular Health of Women Treated for Cancer: Understanding the Long-Term Risks
At the 2023 Global Cardio-Oncology Summit in Madrid, in a joint session with ASCO and the International Cardio-Oncology Society, Anita Arnold, DO, FACC, MBA, Director, Noninvasive Cardiology, and Director of Cardio-Oncology, Lee Memorial Health Systems, Fort Myers, Florida, discussed the...
Expert Point of View: Valentina Guarneri, MD
Invited discussant of the HER2CLIMB-02 trial, Valentina Guarneri, MD, of Padeva Istituto Oncologica Veneto, Italy, hailed these results as important, especially for patients with HER2-positive breast cancer and brain metastases. However, she noted, “HER2CLIMB-02 is not likely to challenge the...
HER2CLIMB-02: Tucatinib Plus T-DM1 Extends Progression-Free Survival vs T-DM1 Alone in Advanced HER2-Positive Breast Cancer
Adding the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) to the HER2-targeted agent tucatinib extended progression-free survival by about 2 months vs treatment with T-DM1 alone among patients with unresectable, locally advanced or metastatic HER2-positive breast cancer, according to...
W. Kimryn Rathmell, MD, PhD, Begins Work as 17th Director of the NCI
On December 18, W. Kimryn Rathmell, MD, PhD, began her work as the 17th Director of the National Cancer Institute (NCI). Dr. Rathmell was selected by President Biden to succeed Monica M. Bertagnolli, MD, FACS, FASCO, who left NCI to become the Director of the National Institutes of Health (NIH) on...
Eric J. Small, MD, FASCO, Elected ASCO President for 2025–2026 Term
ASCO has elected Eric J. Small, MD, FASCO, to lead as its President beginning in June 2025. Dr. Small, a long-time ASCO member and volunteer, will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 3, 2025. An additional six ASCO members were...
Understanding Racial and Ethnic Disparities in Modern AML Care After the Approval of Venetoclax
Use of venetoclax may increase survival in non-Hispanic Black patients with acute myeloid leukemia (AML), according to recent findings presented by Wang et al at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 955). Background Although the standard treatment...
Psychiatric and Substance Use Disorders May Be Linked to Poorer Outcomes in AML Following Venetoclax Combination Therapies
Researchers have found that patients with psychiatric or substance use disorders may have an increased risk of experiencing poorer outcomes such as early mortality following treatment for acute myeloid leukemia (AML) with venetoclax combination therapies compared with those without a recent history ...
Male Researchers Lead the Majority of NIH’s Active R01 Grants in Classical Hematology Research
Investigators have found that in the past decade, a majority of the National Institutes of Health’s (NIH) active R01 grants related to classical, nonmalignant hematology were led by male investigators, according to new findings presented by Khan et al at the 2023 American Society of Hematology...
ACS10 Score May Help Inform Treatment, Reduce Racial Disparities in Black Pediatric Patients With AML
Researchers may have uncovered a close link between genetic factors and racial disparities in pediatric patients with acute myeloid leukemia (AML), according to new findings presented by Lamba et al at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 386)....
New Guideline Offers Much-Needed Support in the Treatment of Neuroendocrine Tumors
An ASCO guideline has been developed to inform the use of systemic treatments for metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).1 The guideline helps fill a knowledge gap among community oncologists in particular, who typically do not see many of these rare ...
Chemotherapy Induction Before Chemoradiotherapy Improves Survival in Locally Advanced Cervical Cancer
In patients with newly diagnosed, locally advanced cervical cancer, induction chemotherapy prior to chemoradiation therapy led to a 35% reduction in the risk for disease recurrence or death (hazard ratio [HR] = 0.65; P = .013) and a 39% reduction in the survival hazard (HR = 0.61; P = .04),...
Expert Point of View: Kerin B. Adelson, MD, MHCDS
Discussant of these abstracts on the Oncology Care Model (OCM), Kerin B. Adelson, MD, MHCDS, Chief Quality and Value Officer at The University of Texas, MD Anderson Cancer Center, suggested the OCM was beneficial for both patients and health professionals despite the lack of clear positive ...
Oncology Care Model: Studies Find Significant Savings but Minor Quality Improvement
A pair of studies evaluating the impact of the Oncology Care Model (OCM) has highlighted challenges in improving quality of the value-based payment model, according to data presented at the 2023 ASCO Quality Care Symposium. Both studies were conducted by the Centers for Medicare & Medicaid...
BEATcc Trial: Atezolizumab-Based Regimen Improves Outcomes in First-Line Setting for Advanced Cervical Cancer
In patients with recurrent or metastatic cervical cancer, the addition of the PD-L1–inhibiting monoclonal antibody atezolizumab to first-line chemotherapy plus the angiogenesis inhibitor bevacizumab significantly improved all efficacy outcomes and yielded a median overall survival that exceeded 2.5 ...
Expert Point of View: Elizabeth Smyth, MD
ASCO discussant Elizabeth Smyth, MD, a consultant medical oncologist at Oxford University Hospitals National Health Service Foundation Trust in the United Kingdom, commented on the EDGE-Gastric trial. This regimen, which evaluated dual checkpoint blockade with next-generation agents, aims to...
Early Data Show Novel Immunotherapy Regimen May Improve Outcomes in Advanced Gastric Cancer
Initial findings from the global phase II EDGE-Gastric trial indicate the potential for two novel immune checkpoint inhibitors to improve outcomes in advanced gastroesophageal adenocarcinoma. The findings were reported at the November 2023 ASCO Plenary Session by Yelena Y. Janjigian, MD, Chief of...
Supportive Parents and Early Love of Science Lead to a Career in Hematology Oncology for Nina Shah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Nina Shah, MD, Global Head of Multiple Myeloma Clinical Development and Strategy, Hematology, Oncology Research and Development at AstraZeneca. She is a hematologist who specializes in...
Remembering Cancer Prevention and Health Equity Champion Worta J. McCaskill-Stevens, MD, MS
ASCO and the oncology community are deeply saddened by the death of medical oncologist Worta J. McCaskill-Stevens, MD, MS, on November 15, 2023. Dr. McCaskill-Stevens served as Chief of the National Cancer Institute (NCI) Community Oncology and Prevention Trials Research Group and Director of the...
Sustained MRD Negativity Achieved With Isa-KRd in Newly Diagnosed Multiple Myeloma
For the treatment of newly diagnosed multiple myeloma with high-risk features, a quadruplet regimen of the anti-CD38 antibody isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) induced high rates of measurable residual disease (MRD) negativity, both in transplant-eligible and...
Some Breast Cancer Survivors May Safely De-escalate Mammography 3 Years After Surgery
Women aged 50 or older who had less-frequent mammography 3 years after curative surgery for early-stage breast cancer had similar outcomes as women who had annual mammography, according to results from the Mammo-50 trial presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-02)....
Skipping Adjuvant Radiotherapy May Not Impact Risk of Recurrence or Progression in Patients With Low-Risk DCIS
Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable 5-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the 2023 San...
Understanding the Treatment Options for PD-1–Refractory Melanoma
For the treatment of advanced melanoma that is refractory to anti–PD-1 antibodies, there is no standard approach. The various options, with a look to the future, were discussed by Melinda L. Yushak, MD, MPH, Assistant Professor of Hematology and Oncology at Emory University School of Medicine, at...
Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy
Almost all postmenopausal patients aged 50 to 69 with stage I hormone receptor–positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease-free 5 years after surgery, according to results from the IDEA clinical trial presented at the 2023 San...
Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer
Patients with metastatic breast cancer who took part in a 9-month structured exercise program reported less fatigue and an improved quality of life compared to those who did not participate in the exercise program, according to results from the PREFERABLE-EFFECT trial presented at the 2023 San...
Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
A combination of two HER2-targeted drugs—tucatinib and ado-trastuzumab emtansine (T-DM1), extended progression-free survival among patients with unresectable, locally advanced, or metastatic HER2-positive breast cancer compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial...
Consuming Navy Beans May Improve Gut Health, Regulate Immune and Inflammatory Processes in Colorectal Cancer Survivors
Researchers have uncovered that the regular consumption of navy beans may help modulate markers linked to obesity and disease and improve the gut microbiome in colorectal cancer survivors, according to a novel study published by Zhang et al in eBioMedicine. Background Obesity, poor diet, and...
Expert Point of View: Elizabeth Smyth, MD
Invited discussant, Elizabeth Smyth, MD, a consultant in gastrointestinal oncology at the Oxford University Hospitals NHS Foundation Trust in the United Kingdom, commented on the notable impact in pathologic complete response rates with the addition of checkpoint inhibitors in MATTERHORN and...
Expert Point of View: Miriam Koopman, MD, PhD
Abstract discussant Miriam Koopman, MD, PhD, Professor of Medical Oncology at the University Medical Center, Utrecht, the Netherlands, and Vice Chair of the Dutch Colorectal Cancer Group, commented that CodeBreaK 300 showed a high degree of tumor shrinkage and a significant progression-free...
Expert Point of View: Andrea Apolo, MD
Invited discussant Andrea Apolo, MD, of the National Cancer Institute in Bethesda, Maryland, emphasized that the EV-302/KEYNOTE-A39 and CheckMate 901 trials mark a significant achievement. “Outperforming chemotherapy in first-line therapy is monumental for our field. The two studies presented are...
Expert Point of View: Laura Locati, MD, PhD
Invited discussant of the LIBRETTO-531 trial, Laura Locati, MD, PhD, Associate Professor of Medical Oncology, Department of Internal Medicine and Therapeutics, University of Pavia and Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Italy, commented: “Selpercatinib is a new...
Novel AI Model May Predict Nonsmokers at High Risk for Lung Cancer
An artificial intelligence (AI) model may be capable of using routine chest x-ray images to identify nonsmokers who may be at high risk for lung cancer, according to new findings presented by Walia et al at the Radiological Society of North American (RSNA) 2023 Scientific Assembly and Annual...
Ultraprocessed Food May Heighten Risk of Head and Neck Cancer and Esophageal Adenocarcinoma
A higher consumption of ultraprocessed foods may be associated with the development of cancer of the upper–aerodigestive tract such as head and neck cancer and esophageal adenocarcinoma, according to a recent study published by Morales-Berstein et al in the European Journal of Nutrition. The new...
Expert Point of View: Marina C. Garassino, MD
Formal discussant of the ALINA trial Marina C. Garassino, MD, of the University of Chicago, agreed these results are “impressive and practice changing.” However, she said, at this point, more consideration is needed before jettisoning chemotherapy. “I don’t think we should stop giving adjuvant...
